Efficacy of Panobinostat for the Treatment of Multiple Myeloma
Table 1
Drug summary.
Generic drug name
Panobinostat
Market name (pharmaceutical company)
Farydac® (Novartis)
Phase
Approved
Indication
In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent
Pharmacology description/mechanism of action
HDAC inhibitor
Route of administration
Oral
Chemical structure
2-Hydroxypropanoic acid, compound with 2-(E)-N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide [1 : 1]
Pivotal trial (s)
Panorama 1
Metabolism and elimination
Extensively metabolized, eliminated equally through the kidney and liver
